Dr. Silverman Brings 40 Years’ Expertise in Osteoporosis and Bone Healing
Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid (“CBD”) and synthetic CBD medicines that address the unmet needs of large patient populations, today announced that a leading international expert in osteoporosis and chronic pain, Dr. Stuart Silverman, M.D., FACP, FACR, has joined its Scientific Advisory Board.
Commenting on his appointment, Dr. Silverman said, “Kalytera has assembled a world-class team of scientific, clinical and business leaders — all focused on tackling a critically important medical mission, developing a next generation of therapeutic pharmaceutical products based on CBD or its derivatives. I believe the important work we are doing will improve the bone health, relieve the suffering, and minimize side effects for hundreds of millions of people with bone disease and delayed fracture healing. I am delighted to join Kalytera and its team of internationally esteemed experts.”
“Dr. Silverman is a highly respected and influential authority on osteoporosis and bone health,” said Seth Yakatan, Interim Chief Executive Officer of Kalytera. “He has published, and lectured on these topics globally across Asia, Europe, Latin America, the Middle East as well as the United States. We value his guidance as we advance our CBD and synthetic CBD scientific research as detailed in our recently announced CBD bone-healing research agreement with Tel Aviv University’s Ramot. I am pleased to welcome Dr. Silverman to Kalytera.”
Dr. Stuart Silverman, M.D., FACP, FACR
With 40 years’ experience, Dr. Silverman is board-certified in internal medicine, rheumatology and allergy-immunology. He is currently in private practice and has served as medical director of the Bone Center of Excellence at Cedars-Sinai Medical Center in Los Angeles.
He is also Medical Director of the OMC Clinical Research Center, a nonprofit public benefit corporation, whose mission is bringing cutting-edge research and education to the community. The OMC runs clinical trials for patients with fibromyalgia, osteoporosis, women’s health, osteoarthritis and rheumatoid arthritis. The OMC has been the recipient of both federal (NIH) and state grants and is a member of the National Bone Health Association. He received the 2014 Health Network award for excellence in clinical research.
Dr. Silverman lectures internationally and domestically on his areas of expertise featuring fibromyalgia and osteoporosis. He is the American Society of Bone and Mineral Research (ASBMR) representative to the National Osteoporosis Foundation Interspecialty Medical Council, and a member of the Council of Scientific Advisors of the International Osteoporosis Foundation. He is the developer of the Osteoporosis Assessment Questionnaire, or OPAQ, a measure of quality of life in osteoporosis used globally. He was part of the original WHO task force that developed FRAX, an international algorithm to assess ten-year fracture risk. He has served on a Joint Commission to develop process measures to assess quality of hospital care in osteoporosis. Dr. Silverman is currently a Clinical Professor of Medicine at UCLA and Attending Physician at Cedars-Sinai Medical Center in Los Angeles. He is the author of over 200 original articles, 100 abstracts and ten book chapters.
Kalytera Therapeutics, Inc. is a pharmaceutical company that is developing a portfolio of nonpsychoactive cannabinoid and cannabinoid-modulating medicines that address the unmet needs of large patient populations. The Company seeks to commercialize its proprietary, synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone healing and osteoporosis. For more information, visit: https://kalytera.co/.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.